Login / Signup

Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years.

Christina Charles-SchoemanJon T GilesNancy E LaneErnest H S ChoyDaniel E FurstJiri VencovskyAnthony G WilsonGerd-Rüdiger R BurmesterDerek CoombsSara K PennNasser KhanJillian B YeeKassim RahawiIain B McInnes
Published in: Rheumatology and therapy (2024)
The results of this integrated long-term analysis of laboratory parameters continue to support an acceptable safety profile of UPA 15 mg QD for moderate-to-severe RA.
Keyphrases
  • rheumatoid arthritis
  • disease activity
  • ankylosing spondylitis
  • electronic health record
  • high intensity
  • big data
  • early onset
  • systemic lupus erythematosus
  • machine learning
  • idiopathic pulmonary fibrosis